Roquefort Therapeutics (LON:ROQ) Shares Down 11.1% – What’s Next?

Shares of Roquefort Therapeutics plc (LON:ROQ) were down 11.1% during trading on Friday . The company traded as low as GBX 1.20 and last traded at GBX 1.20. Approximately 219,883 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 1,157,323 shares. The stock had previously closed at GBX 1.35.

Roquefort Therapeutics Price Performance

The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The stock has a market capitalization of £1.96 million, a price-to-earnings ratio of -1.90 and a beta of 0.05. The business’s 50 day simple moving average is GBX 1.44 and its 200-day simple moving average is GBX 1.64.

Insider Activity

In other news, insider Dr Darrin Disley acquired 5,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were acquired at an average cost of GBX 170 per share, with a total value of £8,500,000. Corporate insiders own 23.53% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.